Endpoint analysis of tumors from DMSO- and Aza-treated groups by flow cytometry revealed that CD8+ T cells were no longer elevated in uncontrolled or regressing Aza-treated tumors compared to vehicle, while the increased presence of CD4+ T cells could be observed in the regressing tumor, but not in the uncontrolled Aza-treated tumor (Supplementary Figures 3B, 4E,F). The gene discussed is CD4; the disease is neoplasm.